Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q4 2020 Earnings Presentation
9 slides from Angiodynamics's earnings presentation, Jul 16, 2020
Slide 1: Fourth Quarter 2020 Earnings Presentation
AngioDynamics Fourth Quarter 2020 Earnings Presentation July 16, 2020 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, c
Slide 3: Fourth Quarter and FY2020 Highlights
Fourth Quarter and FY2020 Highlights Financial Performance Product Family Year-over-Year Sales Growth Vascular Interventions and Therapies Q4 FY20 (in millions) Q4 FY20 Q4 FY19 Change AngioVac® (11%) 28% Revenue $58.3 $71.2 (18.1%) Thrombolytic 12% 10% Core Peripheral (24%) (4%) Revenue Excluding As
Slide 4: Fourth Quarter and YTD FY2020 Results (unaudited)
Fourth Quarter and YTD FY2020 Results (unaudited) FY2020 FY2019 FY2020 FY2019 $ in thousands (except per share data) Q4 Q4 Change YTD YTD Change Revenue $58,332 $71,182 (18.1%)* $264,157 $270,634 (2.4%)* Vascular Interventions and Therapies 22,090 31,030 (28.8%)* 112,706 119,901 (6.0%)* Vascular Acc
Slide 5: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 5
Slide 6: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Before Goodwill Impairment
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Before Goodwill Impairment* Amounts in thousands 6
Slide 7: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Amounts in thousands (1) Write-off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company’s acquisition of RadiaDyne. These inventory items were deemed unmarketable absent subse
Slide 8: Reconciliation of Net Income (Loss) to Adjusted EBITDA
Reconciliation of Net Income (Loss) to Adjusted EBITDA Amounts in thousands 8
Slide 9: Growth through Focus Execution Accountability
Growth through Focus Execution Accountability 9